MATTHEW BECKWITH: Open Payments
NPI 1235162280 · HAGERSTOWN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$871 in 44 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $119 · 2025 $871
Food & beverage: $871
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 6 | $143 |
| Novo Nordisk Inc | 7 | $138 |
| AstraZeneca Pharmaceuticals LP | 6 | $138 |
| PFIZER INC. | 8 | $136 |
| Phathom Pharmaceuticals, Inc. | 4 | $58 |
| Abbott Laboratories | 2 | $49 |
| Kowa Pharmaceuticals America, Inc. | 3 | $47 |
| Medtronic, Inc. | 2 | $37 |
| Lilly USA, LLC | 2 | $35 |
| Astellas Pharma US Inc | 1 | $29 |
Products named: TRELEGY ELLIPTA, PREVNAR 20, Ozempic, BREZTRI, AIRSUPRA, VOQUEZNA, ELIQUIS, FREESTYLE LIBRE 3.
Industry payments across MD — which companies pay providers there.
